Second Exit in Eight Months
Dr. Vinay Prasad, the FDA's top vaccine regulator, is leaving the agency in April — marking his second abrupt departure in less than a year. FDA Commissioner Marty Makary announced the move to staff late Friday, saying Prasad would return to his academic position at UC San Francisco. Prasad previously lost his job in July 2025 before being reinstated less than two weeks later, a whiplash sequence that underscored the political turbulence roiling the agency.
Prasad drew fire for overriding career scientists and rejecting specialty drugs for rare diseases, according to The New York Times. His tenure was defined by controversial policy reforms: a 2-to-1 pivotal trial requirement, national priority reviews, a risk-stratified COVID vaccine framework, and what Makary called a "plausible mechanism framework." Critics argued these changes slowed approvals and dismissed established safety protocols.
Regulatory Delays Mount as Staff Hemorrhage
Prasad's exit arrives as FDA watchers sound alarm bells about "chaos" inside the agency. At the CNBC Cures Summit, experts warned that scientific and political pressures are colliding at the FDA, delaying rare disease treatments for patients with few or no options. The agency's internal dysfunction is visible in its recent leucovorin approval — greenlit for the ultra-rare cerebral folate deficiency after the Trump administration touted it as an autism treatment from the Oval Office. The FDA's Tuesday approval carefully sidestepped the autism indication, a course correction that highlights the political minefields career scientists now navigate.
Meanwhile, a separate Environmental Working Group analysis revealed the FDA failed to perform safety checks on more than 100 food ingredients widely used in products like Capri Sun drinks, Kettle and Fire broth, and Quaker Oats snack bars. The review of federal records shows firms are exploiting loopholes to introduce new chemicals into the food system without regulatory review — a breakdown in oversight occurring as the agency hemorrhages institutional knowledge.
What to Watch
Prasad's replacement will inherit an agency in crisis. Staff departures are accelerating, regulatory timelines are stretching, and political appointees are clashing with career scientists over approval standards. Prediction market traders should watch for delays in orphan drug approvals, particularly in the rare disease space where Prasad's rejected applications created a backlog. The leucovorin approval may signal the FDA is attempting to reclaim scientific credibility after political pressure, but the broader pattern is regulatory paralysis. Makary's next hire will reveal whether the Trump administration doubles down on Prasad's reforms or pivots to stabilize the agency's scientific core.
